EGFR and lung adenocarcinoma: To the best of our knowledge, we are the first to report that the combination of furmonertinib and anlotinib is an effective treatment strategy in a patient with EGFR ex20ins-positive advanced lung adenocarcinoma who was previously treated with platinum-based chemotherapy.